BAX stock forecast, quote, news & analysis

Key Takeaways

• Baxter International shares climbed about 24.1% from the July 14, 2026 closing price of $21.80 to the latest intraday level near $27.05 on Aug. 13, 2026.
• The move was driven mainly by second-quarter 2026 results reported on July 30, with adjusted earnings per share of $0.56 beating consensus estimates near $0.37 and revenue of $2.96 billion topping projections of roughly $2.79 billion.
• Management raised full-year 2026 guidance for reported sales growth, organic sales growth, and adjusted earnings per share, reinforcing the company's turnaround narrative.
• Over the last quarter, BAX has risen about 56% from the May 13, 2026 closing price of $17.31, reflecting sustained improvement that accelerated after the earnings release.
• Key watch items include margin recovery, the Novum IQ LVP shipment and installation hold, tariff-related impacts, and progress toward the company's year-end leverage target.

Baxter International (BAX) Company Overview and Market Position

Baxter International Inc. is a global medical products and therapies company that sells a broad portfolio to hospitals, clinics, surgery centers, and other healthcare providers. Its business is organized around two segments: Medical Products & Therapies, which includes Infusion Therapies & Platforms and Advanced Surgery, and Healthcare Systems & Technologies, which includes Care & Connectivity Solutions and Front Line Care.

Baxter is best known for intravenous solutions, infusion systems, drug compounding, and connected care technologies. The company also supplies hemostats, sealants, and patient support systems. As one of the world's largest providers of sterile IV solutions and infusion therapies, Baxter benefits from scale, established hospital relationships, and recurring demand across acute-care settings. Investors follow BAX closely because it sits at the intersection of hospital utilization trends, medical device innovation, and a multiyear operational turnaround focused on execution, cash flow, and debt reduction.

Baxter International (BAX) Stock Price Performance: Last 30 Days vs. Quarter

In the last 30 days, BAX moved from a closing price of $21.80 on July 14, 2026, to an intraday level near $27.05 on Aug. 13, 2026, a gain of approximately 24.1%. The bulk of that advance occurred on July 30, when the stock jumped from a prior close of $24.77 to close at $26.75, touching $30.00 intraday after the company reported second-quarter results and raised its full-year outlook.

Over the last quarter, the move is larger. From the May 13, 2026 closing price of $17.31 to the latest intraday level near $27.05, BAX has gained roughly 56%. The stock trended higher through June and early July as improving sentiment around the company's execution and cash-flow progress took hold, before the second-quarter report provided a sharper re-rating. The overall pattern shows a steady recovery from mid-teen levels followed by an earnings-driven acceleration.

What Drove BAX Stock Price in the Last 30 Days

The central catalyst was Baxter's second-quarter 2026 earnings report on July 30. The company posted adjusted earnings per share of $0.56, well above consensus estimates near $0.37, on revenue of $2.96 billion, which exceeded analyst projections of roughly $2.79 billion. Sales grew 5% on both a reported and organic basis, with strength in Drug Compounding, IV Solutions, Advanced Surgery, and Patient Support Systems.

Management also raised its full-year 2026 guidance. Adjusted earnings per share guidance moved to $1.95 to $2.15 from the prior range of $1.85 to $2.05. Reported sales growth guidance increased to 3% to 4% from flat to 1%, while organic sales growth guidance rose to 2% to 3% from approximately flat. In the days before the report, TD Cowen lifted its price target to $24 from $20 while maintaining a Hold rating, a modest positive for sentiment.

The results were not without offsets. Adjusted gross margin contracted to 38.6%, reflecting the roll-through of higher-cost inventory produced at the end of 2025 and an unfavorable cost reclassification comparison. Results also included an $0.11 per-share benefit from an IEEPA tariff refund. Infusion Systems revenue remained constrained by the previously disclosed shipment and installation hold of the Novum IQ LVP and Injectables. Even so, the earnings beat, raised outlook, and improved cash flow outweighed margin concerns, driving the stock sharply higher.

What Drove BAX Stock Performance Over the Last Quarter

The broader three-month advance reflects Baxter's improving operational momentum rather than a single news event. Under the company's turnaround framework, management has emphasized the Growth & Performance System, focused on execution, simplification, and value creation. First-half results showed meaningful cash-flow improvement, with operating cash flow from continuing operations of $510 million versus $118 million in the prior-year period and free cash flow of $257 million versus a negative $144 million a year earlier.

Segment-level performance has been broad-based. Medical Products & Therapies grew 7% in the second quarter, led by Drug Compounding and Advanced Surgery, while Healthcare Systems & Technologies grew 4% on strong demand for Care & Connectivity Solutions. Management also reiterated a target of approximately 3.0 times net leverage by the end of 2026 while maintaining an investment-grade credit rating. This combination of better execution, improving cash generation, and balance-sheet progress supported the stock's recovery from the mid-teens in May to the mid-$20s by August.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots designed to scan markets and execute rule-based strategies across a wide range of tickers. While Tickeron offers hundreds of AI trading bots trading thousands of tickers, only top-performing and most relevant bots appear in this section, helping traders narrow their focus. Bots vary by strategy, timeframe, and performance metrics, so investors can review the approaches that align with their own trading style. The page offers a practical starting point for those interested in systematic, data-driven market analysis.

BAX Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor whether Baxter can sustain the second-quarter momentum into the second half of 2026. Management expects margin improvement from higher volumes, cost-structure actions, and the shift of higher-cost inventory roll-through, so gross and operating margin trends will be important signals. The status of the Novum IQ LVP shipment and installation hold is another key item, since a resolution could support Infusion Systems revenue while an extended hold may remain a drag.

Tariff developments also matter. The second quarter included an IEEPA tariff refund benefit, while management has referenced a roughly $40 million net tariff impact for the year. Beyond company-specific factors, hospital procedure volumes, capital equipment demand, competition in IV solutions and infusion systems, and progress toward the year-end net leverage target of approximately 3.0 times are likely to shape investor sentiment. Upcoming quarterly results and any updates to full-year guidance will provide the next concrete checkpoints.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations